 Katja Aviszus
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocyte Subsets | 5 | 2020 | 79 | 0.870 |
Why?
| | Clonal Anergy | 5 | 2012 | 54 | 0.590 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2012 | 20 | 0.370 |
Why?
| | B-Lymphocytes | 10 | 2015 | 875 | 0.350 |
Why?
| | Antibody Formation | 2 | 2012 | 291 | 0.350 |
Why?
| | Fatty Acid-Binding Proteins | 3 | 2026 | 79 | 0.320 |
Why?
| | Immunologic Memory | 2 | 2007 | 366 | 0.260 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2007 | 41 | 0.260 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2026 | 919 | 0.260 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 5 | 2013 | 19 | 0.250 |
Why?
| | Self Tolerance | 3 | 2012 | 26 | 0.240 |
Why?
| | Immunoglobulin Variable Region | 7 | 2011 | 80 | 0.230 |
Why?
| | Immunoglobulin G | 5 | 2017 | 886 | 0.200 |
Why?
| | Mice, Inbred A | 5 | 2012 | 48 | 0.200 |
Why?
| | Spleen | 3 | 2015 | 507 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 130 | 0.200 |
Why?
| | Cell Differentiation | 3 | 2007 | 2033 | 0.200 |
Why?
| | Macrophages, Alveolar | 1 | 2026 | 368 | 0.190 |
Why?
| | p-Azobenzenearsonate | 3 | 2012 | 5 | 0.170 |
Why?
| | Autoimmunity | 4 | 2013 | 928 | 0.170 |
Why?
| | Autoantigens | 3 | 2014 | 425 | 0.170 |
Why?
| | PPAR gamma | 1 | 2022 | 177 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 989 | 0.160 |
Why?
| | Adoptive Transfer | 4 | 2017 | 197 | 0.160 |
Why?
| | Mice, Transgenic | 7 | 2012 | 2177 | 0.160 |
Why?
| | Genes, Immunoglobulin | 4 | 2010 | 29 | 0.150 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2020 | 93 | 0.150 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2020 | 97 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 2 | 2015 | 412 | 0.150 |
Why?
| | Mice | 18 | 2026 | 18218 | 0.140 |
Why?
| | Berylliosis | 1 | 2020 | 202 | 0.140 |
Why?
| | Mice, Knockout | 5 | 2026 | 3106 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 628 | 0.130 |
Why?
| | Antibodies, Antinuclear | 3 | 2014 | 62 | 0.130 |
Why?
| | Antigen-Antibody Complex | 1 | 2017 | 70 | 0.120 |
Why?
| | Receptors, Antigen, B-Cell | 3 | 2014 | 133 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2023 | 2134 | 0.120 |
Why?
| | Mutation | 3 | 2022 | 4068 | 0.120 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2010 | 237 | 0.110 |
Why?
| | Mice, Inbred C57BL | 6 | 2015 | 5954 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Autoantibodies | 3 | 2015 | 1504 | 0.110 |
Why?
| | Interleukin-4 | 1 | 2015 | 206 | 0.110 |
Why?
| | Haptens | 2 | 2007 | 21 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 764 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2017 | 1129 | 0.110 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 341 | 0.110 |
Why?
| | Animals | 18 | 2026 | 37800 | 0.100 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 84 | 0.090 |
Why?
| | Immunoglobulin M | 1 | 2014 | 280 | 0.090 |
Why?
| | Hybridomas | 3 | 2007 | 233 | 0.090 |
Why?
| | Hemocyanins | 3 | 2007 | 60 | 0.090 |
Why?
| | Germ-Line Mutation | 2 | 2005 | 175 | 0.090 |
Why?
| | Cells, Cultured | 3 | 2015 | 4102 | 0.090 |
Why?
| | Immunoglobulin kappa-Chains | 4 | 2011 | 23 | 0.080 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 175 | 0.080 |
Why?
| | Lymphocyte Activation | 2 | 2004 | 1123 | 0.070 |
Why?
| | Immune Tolerance | 2 | 2017 | 378 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.070 |
Why?
| | Antibodies, Monoclonal | 3 | 2017 | 1501 | 0.070 |
Why?
| | Antibody Affinity | 1 | 2007 | 60 | 0.070 |
Why?
| | CD40 Ligand | 1 | 2007 | 39 | 0.070 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2005 | 85 | 0.070 |
Why?
| | Antibody Specificity | 1 | 2007 | 178 | 0.060 |
Why?
| | Immunization, Secondary | 1 | 2007 | 92 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2011 | 691 | 0.060 |
Why?
| | Macrophages | 2 | 2022 | 1496 | 0.060 |
Why?
| | Immunoglobulin mu-Chains | 2 | 2003 | 8 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2026 | 45 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2026 | 67 | 0.060 |
Why?
| | Antibody Diversity | 1 | 2005 | 16 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2589 | 0.060 |
Why?
| | Transgenes | 2 | 2003 | 190 | 0.060 |
Why?
| | Protein Binding | 2 | 2021 | 2241 | 0.050 |
Why?
| | Inflammation | 3 | 2026 | 2862 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2007 | 770 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2026 | 440 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 138 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2022 | 120 | 0.040 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 50 | 0.040 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 88 | 0.040 |
Why?
| | CD11c Antigen | 1 | 2020 | 40 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 121 | 0.040 |
Why?
| | Receptors, Virus | 1 | 2021 | 96 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 661 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2001 | 159 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 146 | 0.040 |
Why?
| | Receptors, Fc | 1 | 2020 | 54 | 0.040 |
Why?
| | T-Box Domain Proteins | 1 | 2020 | 106 | 0.040 |
Why?
| | Receptors, Complement 3d | 1 | 2020 | 142 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2001 | 320 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 206 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 572 | 0.040 |
Why?
| | Humans | 10 | 2026 | 144298 | 0.040 |
Why?
| | Gene Expression | 3 | 2014 | 1474 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 518 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2020 | 370 | 0.030 |
Why?
| | Oligonucleotides | 1 | 1999 | 151 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2002 | 516 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 369 | 0.030 |
Why?
| | Kinetics | 1 | 2021 | 1603 | 0.030 |
Why?
| | Base Sequence | 4 | 2003 | 2171 | 0.030 |
Why?
| | Binding Sites | 1 | 2021 | 1306 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2022 | 2808 | 0.030 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 50 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1152 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2005 | 2348 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2844 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.030 |
Why?
| | Germinal Center | 1 | 2015 | 67 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 245 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2896 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2014 | 13 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2020 | 1158 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 396 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 396 | 0.020 |
Why?
| | Endocytosis | 1 | 2014 | 167 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3595 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 971 | 0.020 |
Why?
| | Radiation Chimera | 1 | 2011 | 27 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1160 | 0.020 |
Why?
| | Complementarity Determining Regions | 1 | 2010 | 53 | 0.020 |
Why?
| | Codon | 2 | 2002 | 93 | 0.020 |
Why?
| | Cell Membrane | 1 | 2014 | 704 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2011 | 364 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 331 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 303 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2010 | 205 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 10783 | 0.020 |
Why?
| | Arginine | 1 | 2010 | 238 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8265 | 0.020 |
Why?
| | snRNP Core Proteins | 1 | 2007 | 4 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1174 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2007 | 37 | 0.020 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2007 | 24 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2006 | 43 | 0.020 |
Why?
| | Receptors, Complement | 1 | 2006 | 125 | 0.010 |
Why?
| | Mice, Inbred NZB | 1 | 2005 | 16 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1981 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 495 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 14092 | 0.010 |
Why?
| | Arsanilic Acid | 1 | 2003 | 1 | 0.010 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2003 | 11 | 0.010 |
Why?
| | Immunoglobulin Class Switching | 1 | 2003 | 21 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2003 | 156 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2005 | 1246 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2003 | 368 | 0.010 |
Why?
| | Epitopes | 1 | 2004 | 479 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2003 | 322 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2127 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2007 | 842 | 0.010 |
Why?
| | Chromatin | 1 | 2005 | 554 | 0.010 |
Why?
| | Immunoglobulin delta-Chains | 1 | 2001 | 2 | 0.010 |
Why?
| | Cell Lineage | 1 | 2003 | 376 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 409 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2004 | 667 | 0.010 |
Why?
| | Aged | 1 | 2020 | 25901 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 2001 | 119 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4525 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 272 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1762 | 0.010 |
Why?
| | Base Composition | 1 | 1999 | 82 | 0.010 |
Why?
| | Immunoglobulin Light Chains | 1 | 1999 | 51 | 0.010 |
Why?
| | Point Mutation | 1 | 2000 | 242 | 0.010 |
Why?
| | DNA Primers | 1 | 2000 | 507 | 0.010 |
Why?
| | RNA Splicing | 1 | 2000 | 286 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 35892 | 0.010 |
Why?
| | Alleles | 1 | 2001 | 881 | 0.010 |
Why?
| | DNA Repair | 1 | 2000 | 256 | 0.010 |
Why?
| | Male | 2 | 2020 | 72263 | 0.010 |
Why?
| | Adult | 1 | 2020 | 40408 | 0.010 |
Why?
| | Female | 2 | 2020 | 78137 | 0.010 |
Why?
| | Kidney | 1 | 2004 | 1493 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1999 | 728 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2000 | 1465 | 0.010 |
Why?
| | RNA | 1 | 2000 | 926 | 0.010 |
Why?
| | Biomarkers | 1 | 2001 | 4248 | 0.000 |
Why?
|
|
Aviszus's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|